bioAffinity quarterly CyPath Lung test sales double, up more than 200% year over year
PUBT · 07/07 12:46
Share
Listen to the news
- bioAffinity Technologies reported Q2 2026 CyPath Lung test sales up more than 30% from Q1 2026, doubling to a new quarterly record.
- Q2 tests sold rose more than 200% from Q2 2025, extending year-over-year growth above 200%.
- Nearly 3,000 CyPath Lung tests have been performed since commercial launch, reflecting broader adoption across pulmonology and medical-center settings.
- Financial results for Q2 2026 are scheduled for release in August.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260707410622) on July 07, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved